Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

Genmab discontinued the development of the antibody-drug conjugate (ADC) GEN1107, acquired via its $1.8 billion buyout of ProfoundBio in 2024, due to an inadequate benefit-risk profile1 3 7 9.

GEN1107 was a clinical-stage ADC targeting protein tyrosine kinase 7 (PTK7); its Phase 1/2 trial was terminated in August 2025 after launching in January 20241 3 9.

This move adds to the ongoing consolidation and shifting priorities in the ADC space, paralleling Johnson & Johnson's buyout of Ambrx, another player in the ADC/oncology field.

Genmab acquired three clinical ADC assets in the ProfoundBio deal:
GEN1107, rinatabart sesutecan (Rina-S), and GEN11601 2 4. While GEN1107 was discontinued, Rina-S (targeting folate receptor alpha) and GEN1160 (targeting CD70) remain under development, although GEN1160 was subsequently dropped as well due to low trial enrollment1 5.

The discontinued GEN1107 and ongoing Rina-S program are part of a lawsuit filed by AbbVie alleging trade secret theft by ProfoundBio and Genmab; both companies deny the allegations and pledge to contest the case1 3.

Genmab's actions reflect a broader trend of asset prioritization and increased legal scrutiny in the ADC marketplace, which has seen recent M&A activity such as J&J’s $2 billion acquisition of Ambrx focused on similar next-generation ADCs.